Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of "Buy" by Brokerages

Shares of Celcuity Inc. (NASDAQ:CELC - Get Free Report) have received a consensus recommendation of "Buy" from the seven research firms that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $29.17.

CELC has been the topic of several recent analyst reports. Stifel Nicolaus upped their target price on Celcuity from $39.00 to $42.00 and gave the company a "buy" rating in a research report on Monday, October 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $23.00 target price on shares of Celcuity in a research report on Friday, November 15th. Lifesci Capital began coverage on Celcuity in a research report on Monday, August 26th. They set an "outperform" rating and a $27.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $27.00 price objective on shares of Celcuity in a report on Friday, November 15th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Quest Partners LLC boosted its stake in shares of Celcuity by 31.3% in the second quarter. Quest Partners LLC now owns 5,788 shares of the company's stock worth $95,000 after buying an additional 1,379 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Celcuity by 9.9% in the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company's stock worth $272,000 after buying an additional 1,500 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Celcuity by 7.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company's stock worth $361,000 after buying an additional 1,600 shares during the last quarter. Acuta Capital Partners LLC boosted its stake in shares of Celcuity by 3.6% in the third quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company's stock worth $695,000 after buying an additional 1,600 shares during the last quarter. Finally, nVerses Capital LLC purchased a new stake in shares of Celcuity in the third quarter worth about $33,000. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Stock Up 5.4 %

NASDAQ:CELC traded up $0.71 during mid-day trading on Monday, hitting $13.90. 309,452 shares of the company's stock traded hands, compared to its average volume of 279,757. The company has a fifty day moving average of $14.90 and a 200 day moving average of $15.86. Celcuity has a twelve month low of $11.51 and a twelve month high of $22.19. The company has a market capitalization of $516.11 million, a P/E ratio of -5.05 and a beta of 0.76. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.